Oakworth Capital Inc. maintained its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. Oakworth Capital Inc.’s holdings in Alexion Pharmaceuticals were worth $243,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently added to or reduced their stakes in ALXN. BlackRock Inc. increased its position in shares of Alexion Pharmaceuticals by 2,689.8% in the first quarter. BlackRock Inc. now owns 18,628,080 shares of the biopharmaceutical company’s stock worth $2,258,467,000 after buying an additional 17,960,356 shares during the period. Vanguard Group Inc. raised its stake in shares of Alexion Pharmaceuticals by 3.1% in the first quarter. Vanguard Group Inc. now owns 14,467,456 shares of the biopharmaceutical company’s stock worth $1,754,034,000 after buying an additional 433,293 shares during the period. State Street Corp raised its stake in shares of Alexion Pharmaceuticals by 6.8% in the first quarter. State Street Corp now owns 11,298,685 shares of the biopharmaceutical company’s stock worth $1,369,846,000 after buying an additional 718,756 shares during the period. Jennison Associates LLC raised its stake in shares of Alexion Pharmaceuticals by 15.8% in the first quarter. Jennison Associates LLC now owns 9,622,914 shares of the biopharmaceutical company’s stock worth $1,166,682,000 after buying an additional 1,309,529 shares during the period. Finally, Ameriprise Financial Inc. raised its stake in shares of Alexion Pharmaceuticals by 8.0% in the first quarter. Ameriprise Financial Inc. now owns 6,149,572 shares of the biopharmaceutical company’s stock worth $745,579,000 after buying an additional 454,069 shares during the period. 95.14% of the stock is currently owned by hedge funds and other institutional investors.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded up 0.48% during midday trading on Friday, reaching $132.93. The company had a trading volume of 1,312,700 shares. The company has a market capitalization of $29.67 billion, a P/E ratio of 57.65 and a beta of 1.41. Alexion Pharmaceuticals, Inc. has a 1-year low of $96.18 and a 1-year high of $145.42. The firm has a 50-day moving average of $129.36 and a 200 day moving average of $122.92.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The company had revenue of $912 million during the quarter, compared to analysts’ expectations of $846.15 million. During the same quarter last year, the firm earned $1.13 earnings per share. The firm’s quarterly revenue was up 21.1% compared to the same quarter last year. On average, equities research analysts forecast that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://stocknewstimes.com/2017/08/12/oakworth-capital-inc-has-243000-stake-in-alexion-pharmaceuticals-inc-alxn-updated.html.
ALXN has been the topic of a number of analyst reports. Barclays PLC reaffirmed an “overweight” rating and set a $155.00 price objective on shares of Alexion Pharmaceuticals in a report on Wednesday, May 24th. UBS AG reissued a “buy” rating and issued a $142.00 price target (up from $140.00) on shares of Alexion Pharmaceuticals in a report on Monday, June 26th. Deutsche Bank AG cut their price target on shares of Alexion Pharmaceuticals from $160.00 to $153.00 and set a “buy” rating on the stock in a report on Thursday, May 25th. Morgan Stanley reaffirmed an “overweight” rating and set a $153.00 price objective (up from $141.00) on shares of Alexion Pharmaceuticals in a report on Friday, July 28th. Finally, Raymond James Financial, Inc. reaffirmed a “strong-buy” rating and set a $176.00 price objective on shares of Alexion Pharmaceuticals in a report on Tuesday, May 9th. Five research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $156.89.
In related news, Director Bros. Advisors Lp Baker bought 1,348,955 shares of the firm’s stock in a transaction that occurred on Wednesday, June 14th. The stock was purchased at an average cost of $116.32 per share, for a total transaction of $156,910,445.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ann M. Veneman sold 700 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $137.74, for a total value of $96,418.00. Following the sale, the director now directly owns 6,315 shares of the company’s stock, valued at $869,828.10. The disclosure for this sale can be found here. Insiders bought 2,019,734 shares of company stock valued at $235,606,846 over the last ninety days. Insiders own 4.35% of the company’s stock.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.